HUP0400979A2 - HGT-NK4 PEG-konjugátumai - Google Patents

HGT-NK4 PEG-konjugátumai

Info

Publication number
HUP0400979A2
HUP0400979A2 HU0400979A HUP0400979A HUP0400979A2 HU P0400979 A2 HUP0400979 A2 HU P0400979A2 HU 0400979 A HU0400979 A HU 0400979A HU P0400979 A HUP0400979 A HU P0400979A HU P0400979 A2 HUP0400979 A2 HU P0400979A2
Authority
HU
Hungary
Prior art keywords
hgt
conjugates
peg
conjugate
kringle
Prior art date
Application number
HU0400979A
Other languages
English (en)
Inventor
Michael Brandt
Apollon Papadimitriou
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of HUP0400979A2 publication Critical patent/HUP0400979A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A találmány tárgya konjugátum, amely áll a hepatocita növekedésifaktor (HGF/SF) N-terminális fragmentumából, ahol ez tartalmazza az a-lánc hajtűdoménjét és négy hurokrégióját (kringle), és mintegy 20 és40 kDa közti össz-molekulatömegű polietilénglikol-csoportból. Anevezett konjugátum javult tulajdonságokkal bír hasznos gyógyszerkénttumor kezeléshez. Ó
HU0400979A 2001-02-23 2002-02-21 HGT-NK4 PEG-konjugátumai HUP0400979A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01104640A EP1234583A1 (en) 2001-02-23 2001-02-23 PEG-conjugates of HGF-NK4
PCT/EP2002/001837 WO2002074344A2 (en) 2001-02-23 2002-02-21 Peg-conjugates of hgt-nk4

Publications (1)

Publication Number Publication Date
HUP0400979A2 true HUP0400979A2 (hu) 2004-08-30

Family

ID=8176596

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400979A HUP0400979A2 (hu) 2001-02-23 2002-02-21 HGT-NK4 PEG-konjugátumai

Country Status (27)

Country Link
US (2) US20030012775A1 (hu)
EP (2) EP1234583A1 (hu)
JP (2) JP2004521139A (hu)
KR (2) KR20090020713A (hu)
CN (1) CN100339393C (hu)
AR (1) AR032574A1 (hu)
AU (1) AU2002233354B2 (hu)
BG (1) BG108125A (hu)
BR (1) BR0207510A (hu)
CA (1) CA2438308A1 (hu)
CZ (1) CZ20032511A3 (hu)
EC (1) ECSP034741A (hu)
GT (1) GT200200038A (hu)
HR (1) HRP20030659A2 (hu)
HU (1) HUP0400979A2 (hu)
IL (1) IL157426A0 (hu)
MA (1) MA26998A1 (hu)
MX (1) MXPA03007130A (hu)
NO (1) NO20033737L (hu)
PA (1) PA8540501A1 (hu)
PE (1) PE20020992A1 (hu)
PL (1) PL367402A1 (hu)
RU (1) RU2293574C2 (hu)
SK (1) SK11652003A3 (hu)
WO (1) WO2002074344A2 (hu)
YU (1) YU65103A (hu)
ZA (1) ZA200306080B (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004019991A2 (en) * 2002-08-30 2004-03-11 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
EP1608680A2 (en) * 2003-03-24 2005-12-28 Novo Nordisk A/S Glp-2 derivatives
JP2007525981A (ja) * 2004-03-03 2007-09-13 エフ．ホフマン−ラ　ロシュ　アーゲー 肝細胞成長因子のｎ末端フラグメントを組み換え発現するための方法
JP4511589B2 (ja) * 2004-03-03 2010-07-28 エフ．ホフマン−ラ ロシュ アーゲー 肝細胞成長因子のｎ末端フラグメントを精製するための方法
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
AU2009234598C1 (en) * 2008-04-09 2012-08-23 Viromed Co., Ltd. Lyophilized DNA formulations for enhanced expression of plasmid DNA
CN102399293B (zh) * 2008-06-03 2013-12-04 中国科学院遗传与发育生物学研究所 一种与纤维蛋白特异结合的重组蛋白及其应用
US10532020B2 (en) 2012-08-22 2020-01-14 Revlon Consumer Products Corporation Nail coatings having enhanced adhesion
RU2679889C2 (ru) 2013-04-18 2019-02-14 Армо Байосайенсиз, Инк. Способы применения интерлейкина-10 для лечения заболеваний и расстройств
CA2914837A1 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
WO2015070060A1 (en) 2013-11-11 2015-05-14 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN106573072A (zh) 2014-06-02 2017-04-19 阿尔莫生物科技股份有限公司 降低血清胆固醇的方法
EP3206713A4 (en) 2014-10-14 2018-06-27 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
CN107106655A (zh) 2014-10-22 2017-08-29 阿尔莫生物科技股份有限公司 使用白细胞介素‑10治疗疾病和病症的方法
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
EP3302547A1 (en) 2015-05-28 2018-04-11 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
AU2016312510A1 (en) 2015-08-25 2018-03-08 Armo Biosciences, Inc. Methods of using Interleukin-10 for treating diseases and disorders
US20220118050A1 (en) * 2019-01-28 2022-04-21 Toray Industries, Inc. Polyethylene glycol-modified form of hepatocyte growth factor or active fragment thereof
US20220220176A1 (en) * 2019-01-28 2022-07-14 Toray Industries, Inc. Polyethylene glycol-modified form of hepatocyte growth factor or active fragment thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0642580B1 (en) 1992-05-18 2002-08-21 Genentech, Inc. Hepatocyte growth factor variants
US6472178B1 (en) 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
GB9225448D0 (en) * 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
RO115788B1 (ro) * 1994-03-31 2000-06-30 Amgen Inc. Polipeptidă mgdf, derivat de polipeptidă mgdf, polipeptidă mgdf mono-pegilată şi procedee de obţinere a acestora
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
EP0816381B1 (en) * 1995-03-10 2004-01-14 NAKAMURA, Toshikazu Polyethylene glycol modified hepatocyte growth factor (hgf)
DE741187T1 (de) * 1995-05-05 1997-04-30 Hoffmann La Roche Rekombinante Obesitäts-(OB)-Proteine
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
ES2275300T3 (es) * 1997-01-15 2007-06-01 Phoenix Pharmacologics, Inc. Factor de necrosis tumoral modificado.
US6133426A (en) * 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
EP0922446A1 (en) * 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
CN1187094C (zh) * 1998-04-28 2005-02-02 应用研究系统Ars股份公司 多元醇干扰素β偶联物
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
PE20010288A1 (es) * 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
MXPA03005406A (es) * 2000-12-20 2003-09-25 Hoffmann La Roche Conjugados de eritropoyetina.

Also Published As

Publication number Publication date
US20030012775A1 (en) 2003-01-16
CA2438308A1 (en) 2002-09-26
PA8540501A1 (es) 2002-09-30
BR0207510A (pt) 2004-07-27
JP2004521139A (ja) 2004-07-15
MXPA03007130A (es) 2003-11-18
AU2002233354B2 (en) 2006-11-30
CN1571679A (zh) 2005-01-26
PL367402A1 (en) 2005-02-21
EP1389132A2 (en) 2004-02-18
CZ20032511A3 (en) 2004-03-17
RU2293574C2 (ru) 2007-02-20
EP1234583A1 (en) 2002-08-28
MA26998A1 (fr) 2004-12-20
US7846896B2 (en) 2010-12-07
BG108125A (bg) 2004-09-30
SK11652003A3 (sk) 2004-05-04
GT200200038A (es) 2002-09-30
NO20033737D0 (no) 2003-08-22
PE20020992A1 (es) 2002-11-01
RU2003127395A (ru) 2005-03-20
KR20030072629A (ko) 2003-09-15
ECSP034741A (es) 2003-10-28
ZA200306080B (en) 2004-11-23
YU65103A (sh) 2006-03-03
WO2002074344A2 (en) 2002-09-26
CN100339393C (zh) 2007-09-26
HRP20030659A2 (en) 2004-08-31
AR032574A1 (es) 2003-11-12
IL157426A0 (en) 2004-03-28
WO2002074344A3 (en) 2003-12-04
NO20033737L (no) 2003-10-21
JP2010174034A (ja) 2010-08-12
KR20090020713A (ko) 2009-02-26
US20080085857A1 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
HUP0400979A2 (hu) HGT-NK4 PEG-konjugátumai
EA200301222A1 (ru) Легочное введение химически модифицированного инсулина
DE60332277D1 (de) Verabreichung von sirnas
NO20044039L (no) Konjugatorer av terapeutiske eller cytotoksiske midler og biologisk aktive peptider.
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
CY1105070T1 (el) Μεθοδος και συνθεσεις που χρησιμοποιουν κιναζολινονες
DK1329458T5 (da) Peptider som sænker blodglucoseniveauer
HK1046912A1 (en) Substituted sapogenins and their use
CY1105963T1 (el) Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
BR0210056A (pt) composições e métodos para tratamento de hiperplasia
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
BG107220A (en) Antitumoral ecteinascudin derivatives
DE60142913D1 (de) Arzneilösungen enthaltend modafinilverbindungen
ATE317849T1 (de) 5-hydroxysapogenin derivate mit aktivität gegen demenz
DE60229867D1 (de) Zielgerichtete ligande gegen peyer's flecke- und/oder m-zellen
DE60224667D1 (de) Perylenequinonen zur anwendung als sonosensitizer
HUP0000523A2 (hu) Éterlipid/kiegészítő alakú lipid kombinációt tartalmazó hordozók és terápiai alkalmazásuk
DE60024977D1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
UY27182A1 (es) Conjugados peg de hgf-nk4
BR0116670A (pt) Preparação para duchas e/ou irrigações de cavidades naturais ou patológicas no corpo humano.
UA33462A (uk) Спосіб переміщення внутрішнього пахвинного кільця при крипторхізмі у дітей
DE29901115U1 (de) Halbzeug zur Herstellung von Schmuckketten oder -reifen
ES2127133A1 (es) Utilizacion de derivados 2,5-dihidroxibencenosulfonicos para la fabricacion de medicamentos destinados al tratamiento y a la prevencion de la enfermedad de alzheimer.